Literature DB >> 9487541

Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms.

J B Dressman1, G L Amidon, C Reppas, V P Shah.   

Abstract

Dissolution tests are used for many purposes in the pharmaceutical industry: in the development of new products, for quality control and, to assist with the determination of bioequivalence. Recent regulatory developments such as the Biopharmaceutics Classification Scheme have highlighted the importance of dissolution in the regulation of post-approval changes and introduced the possibility of substituting dissolution tests for clinical studies in some cases. Therefore, there is a need to develop dissolution tests that better predict the in vivo performance of drug products. This could be achieved if the conditions in the gastrointestinal tract were successfully reconstructed in vitro. The aims of this article are, first, to clarify under which circumstances dissolution testing can be prognostic for in vivo performance, and second, to present physiological data relevant to the design of dissolution tests, particularly with respect to the composition, volume, flow rates and mixing patterns of the fluids in the gastrointestinal tract. Finally, brief comments are made in regard to the composition of in vitro dissolution media as well as the hydrodynamics and duration of the test.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1998        PMID: 9487541     DOI: 10.1023/a:1011984216775

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  36 in total

1.  Transit of pharmaceutical dosage forms through the small intestine.

Authors:  S S Davis; J G Hardy; J W Fara
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

2.  Upper gastrointestinal (GI) pH in young, healthy men and women.

Authors:  J B Dressman; R R Berardi; L C Dermentzoglou; T L Russell; S P Schmaltz; J L Barnett; K M Jarvenpaa
Journal:  Pharm Res       Date:  1990-07       Impact factor: 4.200

3.  Estimation of the increase in solubility of drugs as a function of bile salt concentration.

Authors:  S D Mithani; V Bakatselou; C N TenHoor; J B Dressman
Journal:  Pharm Res       Date:  1996-01       Impact factor: 4.200

4.  Gastric juice as a dissolution medium: surface tension and pH.

Authors:  M Efentakis; J B Dressman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

5.  Regulation of the gastric emptying of glucose.

Authors:  W Brener; T R Hendrix; P R McHugh
Journal:  Gastroenterology       Date:  1983-07       Impact factor: 22.682

6.  Short chain fatty acids in human large intestine, portal, hepatic and venous blood.

Authors:  J H Cummings; E W Pomare; W J Branch; C P Naylor; G T Macfarlane
Journal:  Gut       Date:  1987-10       Impact factor: 23.059

7.  The incidence of achlorhydria and hypochlorhydria in healthy subjects and patients with gastrointestinal diseases.

Authors:  P M Christiansen
Journal:  Scand J Gastroenterol       Date:  1968       Impact factor: 2.423

8.  Gallbladder contraction and its relationship to interdigestive duodenal motor activity in normal human subjects.

Authors:  L Marzio; M Neri; F Capone; F Di Felice; C De Angelis; A Mezzetti; F Cuccurullo
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

9.  Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation.

Authors:  H Brøndsted; J Kopecek
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

10.  Rate and pattern of gastric emptying in humans using 99mTc-labeled triethylenetetraamine-polystyrene resin.

Authors:  M C Theodorakis; G A Digenis; R M Beihn; M B Shambhu; F H DeLand
Journal:  J Pharm Sci       Date:  1980-05       Impact factor: 3.534

View more
  114 in total

1.  Use of 1-methyl-pyrrolidone as a solubilizing agent for determining the uptake of poorly soluble drugs.

Authors:  A S Uch; U Hesse; J B Dressman
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

2.  Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data.

Authors:  E Nicolaides; E Galia; C Efthymiopoulos; J B Dressman; C Reppas
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

3.  Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide.

Authors:  R Löbenberg; J Krämer; V P Shah; G L Amidon; J B Dressman
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

4.  Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration.

Authors:  E Nicolaides; M Symillides; J B Dressman; C Reppas
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

5.  Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media.

Authors:  Edmund S Kostewicz; Ulrich Brauns; Robert Becker; Jennifer B Dressman
Journal:  Pharm Res       Date:  2002-03       Impact factor: 4.200

6.  Modeling heterogeneity of properties and random effects in drug dissolution.

Authors:  P Lánský; M Weiss
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

7.  A comparison of the solubility of danazol in human and simulated gastrointestinal fluids.

Authors:  B L Pedersen; A Müllertz; H Brøndsted; H G Kristensen
Journal:  Pharm Res       Date:  2000-07       Impact factor: 4.200

8.  Rate-limited steps of human oral absorption and QSAR studies.

Authors:  Yuan H Zhao; Michael H Abraham; Joelle Le; Anne Hersey; Chris N Luscombe; Gordon Beck; Brad Sherborne; Ian Cooper
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

9.  Intragastric floating drug delivery system of cefuroxime axetil: in vitro evaluation.

Authors:  Viral F Patel; Natavarlal M Patel
Journal:  AAPS PharmSciTech       Date:  2006-02-24       Impact factor: 3.246

10.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.